Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans? is organized by Physicians' Education Resource, LLC (PER).
Release Date: April 28, 2023
Expiration Date: April 28, 2024
Description:
Over the past few years, several new targeted drugs for breast cancer have received FDA approval based on increased understanding of the diverse genetic etiologies underlying this disease. The use of PARP inhibitors has greatly expanded in patients with BRCA1/2-mutated, hormone receptor-positive (HR+) or triple-negative breast cancer (TNBC). Recent development of novel antibody-drug conjugates (ADCs) that target the HER2/HER3 pathway have resulted in several practice-changing drug approvals for breast cancer. TROP2-directed ADCs have transformed treatment of TNBC, and recent data have shown additional advances for treatment of HR+/HER2-negative disease.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a live satellite symposium held in conjunction with the 40th Annual Miami Breast Cancer Conference® in March 2023. This unique and engaging multimedia activity is ideal for oncologists and focuses on recent clinical developments of oncogenic-targeted therapies and the subsequent implications for breast cancer treatment. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Describe clinical trial evidence from studies that evaluated PARP-, HER2/3-, and TROP2-targeted therapies to manage patients with breast cancer
• Integrate recent evidence on PARP-, HER2/3-, and TROP2-targeted approaches to develop personalized care breast cancer plans
• Determine recent guidelines in parallel with expert recommendations on how genetic testing can be practically incorporated to inform clinical decision-making in breast cancer care settings
• Plan effective strategies to monitor for and manage toxicities associated with PARP-, HER2/3-, and TROP2-targeted in the treatment of breast cancer.